The Rising Influence of Rising Affluence

[DewDiligence]

ABT 2Q22 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency)   
 Medical devices*  33%        +8%     
 Diagnostics       38%       +37%     
 Nutrition         17%        -5%     
 Drugs†            11%        +9%

2Q22 COVID-diagnostics sales were $2.3B, 53% of 2Q22 diagnostics sales.

57% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.